Lees Pharmaceutical Holdings Ltd 2024 SR
The report highlights Lee's Pharmaceutical's commitment to sustainability, focusing on therapeutic areas like cardiovascular and women's health. In 2024, the company established an inter-departmental ESG Working Group and conducted a climate scenario analysis aligned with TCFD recommendations. Key achievements include being named a 'Safe Enterprise' in Hefei and receiving the 'Guangdong Prominent High-tech Products' award for Azilsartan Tablets. The Group also maintained its Caring Company status for the fourth consecutive year and continued its support for ALS patients and cervical cancer prevention.
Company: Lees Pharmaceutical Holdings Ltd
Sector: Health Care
Country: Hong Kong
Year: 2024
Type: SR
Pages: 105
Back to company
Lees Pharmaceutical Holdings Ltd
ESG Report
The report highlights Lee's Pharmaceutical's commitment to sustainability, focusing on therapeutic areas like cardiovascular and women's health. In 2024, the company established an inter-departmental ESG Working Group and conducted a climate scenario analysis aligned with TCFD recommendations. Key achievements include being named a 'Safe Enterprise' in Hefei and receiving the 'Guangdong Prominent High-tech Products' award for Azilsartan Tablets. The Group also maintained its Caring Company status for the fourth consecutive year and continued its support for ALS patients and cervical cancer prevention.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Published
Mar 27, 2025
Type
Sustainability Report
Language
English, Chinese
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Workplace Fatalities
Net Zero Target
Employees